Skip to main content
OpenTrials
Completed

NCT Number: NCT02698436

A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.

This study will compare two different acne treatments for the treatment of acne. Half of the participants will receive two marketed acne products (cleanser and leave-on topical treatment), while the other half of the participants will receive a marketed cleanser and a light-therapy device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

12 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Dermatology Associates, Albuquerque, New Mexico, United States

Loading trial locations.

About this study

Acne is a common chronic skin disease involving blockage and/or inflammation of the hair follicles and their accompanying sebaceous gland.

Benzoyl peroxide (BPO) is one of the most effective and well-studied over-the-counter (OTC) acne therapies, is generally regarded as safe and effective and is considered as a first-line treatment for acne. Topical BPO monotherapy products for at-home acne treatment have been available for OTC use for more than 30 years and studies have indicated that a low dose of BPO may be an effective approach for treating acne using an OTC product when applied consistently to larger areas of the face due primarily to its effects against acne-causing bacteria.

BPO has anti-inflammatory and keratolytic properties, but is thought to act primarily to control P. acnes by releasing reactive oxygen species that are toxic to the bacteria. The most common side effect of topical BPO treatment is skin irritation, which can include erythema, burning, and peeling.

As an alternative to topical OTC standard of care therapies, research has also shown the benefits of red and blue light therapy in the treatment of mild to moderate acne, with red and blue light shown to target the acne-causing bacteria and have an effect on inflammation reduction.

Light-based therapies have been successfully used to treat dermatological conditions since the early 1900's, with various parts of the electromagnetic spectrum (i.e. UV, visible, near-Infrared, etc.) demonstrating different benefits. Light-emitting diodes (LEDs) offer delivery of light to the skin in a gentler manner as compared to light delivered by lasers primarily due to the lower energy output. It has been reported that LEDs do not deliver enough power to damage tissues and do not have the same risk of accidental eye damage that lasers do. Visible-LED light therapy has been deemed a non-significant risk by the Food and Drug Administration and has been approved for use in humans.

This study will look to compare the acne clearing efficacy and tolerance of two different acne treatments: a currently marketed 2.5% BPO full-face topical OTC treatment, and an Investigational red and blue light acne light therapy mask, to determine if the acne resolution efficacy of the Investigational mask is as effective as a current OTC standard of care for at-home treatment of mild to moderate acne.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has mild to moderate acne
  • Has 10 - 100 pimples, 10 - 50 inflamed red pimples, up to 2 raised bumps and no cysts
  • In general good health
  • Must avoid excessive sun exposure and any light treatments or any professional or aesthetic spa-like procedures
  • Must not be pregnant, nursing or intend to become pregnant during the study
  • Must agree to practice a medically acceptable form of birth control.
  • Must be able to read, speak, write and understand English

Exclusion criteria

  • Allergies or sensitivities to product ingredients or to light
  • Has severe acne or pre-existing dermatological facial condition
  • Has an uncontrolled disease or immune deficient disorder
  • Is pregnant, breast-feeding or intending to become pregnant
  • Has been taking prescription drug medication for acne or antibiotics for the past 6 months

Treatment and study plan

Acne Mask

Device

The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes

Other names: Light-Therapy Acne Device

2.5% Benzoyl Peroxide Treatment

Drug

The BPO treatment is applied twice daily, once in the morning and once in the evening

Other names: BPO

Primary outcomes

  1. Percent Change of Global Face Total Acne Lesion Count From Baseline

    Time frame: Baseline to 12 Weeks

Secondary outcomes

  1. Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 1

    Time frame: Baseline to 1 Week

  2. Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 2

    Time frame: Baseline to 2 Weeks

  3. Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 4

    Time frame: Baseline to 4 Weeks

  4. Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 8

    Time frame: Baseline to 8 Weeks

  5. Acne Lesion Counts Total Global Face - Baseline

    Time frame: Baseline

    Acne Lesion Count Total Global Face at Baseline

  6. Acne Lesion Counts Total Global Face - Week 1

    Time frame: 1 Week

    Acne Lesion Count Total Global Face Week 1

  7. Acne Lesion Counts Total Global Face - Week 2

    Time frame: 2 Weeks

    Acne Lesion Count Total Global Face Week 2

  8. Acne Lesion Counts Total Global Face - Week 4

    Time frame: 4 Weeks

    Acne Lesion Count Total Global Face Week 4

  9. Acne Lesion Counts Total Global Face - Week 8

    Time frame: 8 Weeks

    Acne Lesion Count Total Global Face Week 8

  10. Acne Lesion Counts Total Global Face - Week 12

    Time frame: 12 Weeks

    Acne Lesion Count Total Global Face Week 12

  11. Investigator Global Acne Assessment - Baseline

    Time frame: Baseline

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

  12. Investigator Global Acne Assessment - Week 1

    Time frame: 1 Week

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

  13. Investigator Global Acne Assessment - Week 2

    Time frame: 2 Weeks

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

  14. Investigator Global Acne Assessment - Week 4

    Time frame: 4 Weeks

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

  15. Investigator Global Acne Assessment - Week 8

    Time frame: 8 Weeks

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

  16. Investigator Global Acne Assessment - Week 12

    Time frame: 12 Weeks

    Investigator's assessment of subject's acne condition using a score of 0 (best) and 5 (worst) on the Modified Cook's scale.

    0 Clear Residual hyperpigmentation and erythema may be present.

    • Almost Clear. A few scattered comedones and a few (less than five) small papules.
    • Mild.Easily recognizable; less than half the face is involved. Many comedones and many papules and pustules.
    • Moderate More than half of the face is involved. Numerous comedones, papules and pustules.
    • Severe. Entire face is involved. Covered with comedones, numerous papules and pustules and few nodules and cysts.
    • Very Severe.Highly inflammatory acne covering the face; with nodules and cysts present.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide

Industry

Registry information

Official study title

A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne Vulgaris

Acronym: TIGER

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Mar 3, 2016
Registry last updated
Jan 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.